Omega-3 for heart health: B → B
A large cardiovascular outcomes trial missed its primary endpoint; state softened to mixed.
What we said before vs now
Before
Grade B
After
Grade B
modest cardiovascular benefit; large recent trials were mixed
What this does not change
- Interaction profile for Omega-3 — unchanged unless there is a separate severity change.
- Dose guidance — unchanged unless the new evidence altered the studied dose range.
- Safety recommendations — unchanged unless a safety event is recorded separately.
Reviewer & methodology
Reviewed and signed by Substrate editorial (Independent research collective) on . Methodology v1.
See also
Cite this page
Reuse under CC-BY 4.0 with attribution to evidencebased.info.
Plain-text citation
Substrate. Omega-3 for heart health: B → B. https://evidencebased.info/changes/2026-03-20-omega-3-heart-health-b-to-b. Updated 2026-03-20.
BibTeX
@misc{substrate_mega3hearthealthbtob,
author = {Substrate editorial},
title = {Omega-3 for heart health: B → B},
year = {2026},
url = {https://evidencebased.info/changes/2026-03-20-omega-3-heart-health-b-to-b},
note = {evidencebased.info}
}